Clinical Trial

Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Injection

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The succinylated gelatin injection (specification: 500 mL: 20 g) developed and produced by Nanjing Chia-tai Tianqing Pharmaceutical.. is used as the experimental drug, and the succinylated gelatin injection (trade name: Gelofusine) produced by B. Braun Melsungen AG is licensed ®； Specification: 500 mL: 20 g) is used as a control drug to evaluate the clinical equivalence of two formulations in patients planning elective surgery by comparing the changes in stroke volume (SV) between 5 minutes after completion of ANH and immediately before the start of ANH.
Trial Details
NCT Number NCT06977763
Lead Sponsor Nanjing Chia-tai Tianqing Pharmaceutical
Conditions Acute Normovolemic Hemodilution
Enrollment 104 participants
Start Date 2025-07-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-18